SOMAÍ, a leading EU-GMP vertically integrated Multi-Country Operator (MCO), continues its rapid expansion into key global markets with its official launch in Italy.
Partnering with Materia Medica Processing, Italy’s premier pharmaceutical cannabis company, SOMAÍ brings its pharmaceutical-grade, EU-GMP-certified cannabinoid medicines to Italian patients and healthcare professionals.
With an established presence in Australia, the UK, and Germany, as well as announced market entries in Ireland, Poland, and Switzerland, SOMAÍ’s launch in Italy marks another milestone in its mission to deliver premium cannabis-based therapeutics worldwide.
Despite Italy’s long-standing role in the European medical cannabis landscape, patients continue to face barriers to accessing high-quality, standardized treatments. Through this partnership, SOMAÍ introduces scientifically advanced cannabinoid therapies that enhance consistency, accessibility, and innovation in patient care.
With its multi-step extraction process and EU-GMP-certified formulations, SOMAÍ supports healthcare professionals and pharmacies in providing reliable pharmaceutical-grade cannabinoid-based medicines, ensuring greater consistency, accessibility, and innovation in patient care.
Michael Sassano, CEO of SOMAÍ, emphasized the significance of this expansion, stating: “Demand for SOMAÍ products has never been higher, and we’re thrilled to bring our industry-leading extracts to Italy. Our global footprint now spans multiple continents, and this partnership with Materia Medica allows us to integrate our innovative solutions into Italy’s robust medical cannabis framework. SOMAÍ’s dedication to quality and innovation is what sets us apart, and our global expansion has only just begun.”
Founded in 2018 and based in Siena, Tuscany, Materia Medica Processing is a leading pharmaceutical cannabis distributor with cutting-edge EU-GMP authorized facilities and authorization for the distribution of medical-grade cannabis extracts. The company specializes in navigating Italy’s complex regulatory landscape, ensuring that SOMAÍ’s broadest product portfolio reaches patients efficiently and effectively.
Pietro Paolo Crocetta, CEO of Materia Medica Processing, shared his enthusiasm for the partnership: “SOMAÍ brings an unparalleled level of expertise, innovation, and commitment to the medical cannabis sector. This partnership represents a transformative step forward in improving patient access to pharmaceutical-grade cannabinoid therapies in Italy, and we are proud to work alongside SOMAÍ in shaping the future of this industry.”
Italy is the latest addition to SOMAÍ’s expanding global footprint, reinforcing its position as a leader in cannabinoid-based pharmaceuticals. The company is already commercially active in the United Kingdom, Germany, and Australia, with Ireland, Poland, and Switzerland set to launch in 2025.
